每经AI快讯，有投资者在投资者互动平台提问： 公司氟[18F]化钠注射液自2025年5月获批以来，目前 是否有可披露的销售数据（如销量、营收贡献、主要销售区域/渠道等）？ （记者 胡玲） 东诚药业（002675.SZ）12月30日在投资者互动平台表示，目前氟[18F]化钠注射液暂无销售数据，未来 公司会根据相关法律法规的要求，在定期报告中披露产品的经营情况，请您关注公司后续的定期报告和 公告。 ...

中国同辐(01763)发布公告，近日，由原子高科股份有限公司(以下简称：原子高科)参与完成的"儿童神 经母细胞瘤多模态核医学分子影像体系的建立"项目，荣获本年度北京医学科技奖一等奖。 根据首都医科大学附属北京友谊医院(以下简称：友谊医院)发布的数据，神经母细胞瘤是儿童最常见的 颅外实体肿瘤，发病率约占儿童恶性肿瘤的8%-10%，却导致约10%-15%的儿童肿瘤相关死亡。超过一 半的患儿在初诊时即被归为高危组，预后差，5年生存率不足50%。因其高发病率、高复发率与高死亡 率，该病被医学界称为"儿童癌症之王"，不仅是临床诊治中的严峻挑战，更已成为影响我国儿童健康的 重大公共卫生问题。项目以"儿童癌症之王"——神经母细胞瘤为关键突破口，紧密围绕国家在儿童重大 疾病与罕见病防治领域的战略部署，依托多模态核医学分子影像技术，聚焦神经母细胞瘤精准诊疗的核 心瓶颈，历经十年系统攻关，成功构建了从关键设备、核心药物到临床应用的完整自主创新链条，形成 了具有中国特色的"多模态、低剂量、短时程"神经母细胞瘤多模态核医学分子影像精准诊疗体系，为应 对这一世界性难题贡献了中国智慧与中国方案。 原子高科与友谊医院核医学科秉持"产学研医 ...

（股份代號：1763） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 於其他海外監管市場發佈的公告 公司附屬公司榮獲北京醫學科技獎一等獎 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條的規定而發出。 以下公告的中文原稿由中國同輻股份有限公司旗下一間於全國中小企業股份轉讓 系統上市的附屬公司，原子高科股份有限公司（股份代號：430005）於中國境內發 佈。 茲載列原子高科股份有限公司於2025年12月15日於全國中小企業股份轉讓系統網 站(www.neeq.com.cn)刊登的「原子高科股份有限公司關於參與「兒童神經母細胞 瘤多模態核醫學分子影像體系的建立」項目榮獲北京醫學科技獎一等獎的公告」， 僅供參考。 承董事會命 中國同輻股份有限公司 董事長 肖亞飛 中國，北京，2025年12月15日 於 ...

Core Insights - The company reported a decline in revenue and net profit for the first half of 2025, with total revenue at 1.384 billion yuan, down 2.6% year-on-year, and net profit attributable to shareholders at 89 million yuan, down 20.7% [1] Financial Performance - Revenue for the nuclear medicine segment reached 503 million yuan, a year-on-year increase of 0.78%, with a gross margin of 67.27% [2] - The core product, 18F-FDG, generated revenue of 212 million yuan, reflecting an 8.72% increase year-on-year [2] - The raw material drug segment reported revenue of 611 million yuan, down 7.02%, primarily due to a decline in heparin sodium sales prices [2] Development Trends - The company has invested in 7 operational nuclear pharmacies focused on single-photon drugs and 22 on positron emission drugs, with 31 nuclear drug production centers currently in operation [2] - The company’s innovative nuclear drug pipeline is progressing, with the approval of sodium fluoride [18F] injection in May 2025 and ongoing clinical trials for several other products [3] Profit Forecast and Valuation - The company maintains its EPS forecast for 2025 and 2026 at 0.32 yuan and 0.40 yuan, respectively, with the current stock price corresponding to a P/E ratio of 55.1 times for 2025 and 43.9 times for 2026 [4] - The target price has been raised by 16.4% to 19.2 yuan, indicating an 8.8% upside potential from the current stock price [4]

Core Viewpoint - Yantai Dongcheng Pharmaceutical Group Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating potential challenges in its financial performance and operational efficiency [1][2]. Financial Performance - The company's operating revenue for the period was approximately CNY 1.38 billion, a decrease of 2.60% compared to the same period last year [2]. - The net profit attributable to shareholders was approximately CNY 88.65 million, reflecting a decline of 20.70% year-on-year [2]. - The net profit after deducting non-recurring gains and losses was also down, with a reported figure of CNY 88.65 million, marking a 20.72% decrease [2]. - Basic earnings per share were CNY 0.1075, down 20.72% from the previous year [2]. - The weighted average return on net assets was 1.96%, a decrease of 0.37% compared to the previous year [2]. Asset and Equity Position - Total assets at the end of the reporting period were approximately CNY 8.96 billion, an increase of 3.72% from the end of the previous year [3]. - The net assets attributable to shareholders were approximately CNY 4.49 billion, showing a slight increase of 0.16% from the previous year [3]. Shareholder Information - The top shareholder, Yantai Dongyi Biological Engineering Co., Ltd., holds 15.15% of the shares, amounting to approximately 124.89 million shares [6]. - The second-largest shareholder, You Shiyi, holds 12.53% of the shares, equivalent to approximately 103.31 million shares [6]. Significant Events - The company did not distribute cash dividends or issue new shares during the reporting period [1]. - The company has engaged in significant transactions, including the introduction of new investors and capital increases in its subsidiaries [7][8].